Surface Oncology Inc (NASDAQ:SURF) has received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price target of $ 26.00 for the company, according to Zacks. Zacks has also assigned Surface Oncology an industry rank of 187 out of 255 based on the ratings given to its competitors.
SURF has been the topic of several research analyst reports. Goldman Sachs Group initiated coverage on shares of Surface Oncology in a research report on Monday, May 14th. They issued a “neutral” rating and a $ 17.00 price target on the stock. Evercore ISI initiated coverage on shares of Surface Oncology in a research report on Monday, May 14th. They issued an “outperform” rating and a $ 26.00 price target on the stock. Finally, Cowen initiated coverage on shares of Surface Oncology in a research report on Monday, May 14th. They issued an “outperform” rating on the stock.
Surface Oncology opened at $ 13.55 on Thursday, according to MarketBeat.com. Surface Oncology has a 52-week low of $ 12.08 and a 52-week high of $ 15.19.
In other Surface Oncology news, Director David S. Grayzel acquired 100,000 shares of Surface Oncology stock in a transaction dated Monday, April 23rd. The stock was bought at an average cost of $ 15.00 per share, with a total value of $ 1,500,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Ventures Fund I. Llc acquired 266,000 shares of Surface Oncology stock in a transaction dated Monday, April 23rd. The shares were acquired at an average cost of $ 15.00 per share, with a total value of $ 3,990,000.00. The disclosure for this purchase can be found here.
Surface Oncology Company Profile
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.
Get a free copy of the Zacks research report on Surface Oncology (SURF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surface Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Surface Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.